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Abstract
Background Compliant, self-adjusting compression tech-
nology is a novel approach for durable prosthetic fixation
of the knee. However, the long-term survival of these
constructs is unknown.
Questions/purposes We therefore determined the survival
of the Compress1 prosthesis (Biomet Inc, Warsaw, IN,
USA) at 5 and 10 actuarial years and identified the failure
modes for this form of prosthetic fixation.
Methods We retrospectively reviewed clinical and
radiographic records for all 82 patients who underwent
Compress1 knee arthroplasty from 1998 to 2008, as well
as one patient who received the device elsewhere but was
followed at our institution. Prosthesis survivorship and
modes of failure were determined. Followup was for a
minimum of 12 months or until implant removal (median,
43 months; range, 6–131 months); 28 patients were fol-
lowed for more than 5 years.
Results We found a survivorship of 85% at 5 years and
80% at 10 years. Eight patients required prosthetic revision
after interface failure due to aseptic loosening alone (n = 3)
or aseptic loosening with periprosthetic fracture (n = 5).
Additionally, five periprosthetic bone failures occurred that
did not require revision: three patients had periprosthetic
bone failure without fixation compromise and two exhibited
irregular prosthetic osteointegration patterns with concom-
itant fracture due to mechanical insufficiency.
Conclusions Compress1 prosthetic fixation after distal
femoral tumor resection exhibits long-term survivorship.
Implant failure was associated with patient nonadherence
to the recommended weightbearing proscription or with
bone necrosis and fracture. We conclude this is the most
durable FDA-approved fixation method for distal femoral
megaprostheses.
Level of Evidence Level IV, therapeutic study. See
Instructions for Authors for a complete description of
levels of evidence.
Introduction
Megaprostheses need improved bone fixation to reduce
the rate of aseptic loosening associated with stemmed
implants. Young patients cured of tumors have a long life
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expectancy and a compelling need for prosthetic fixation
that is equally long-lasting. A recently developed strategy
is compliant compressive fixation that uses compression,
via a short traction bar, to stimulate osteointegration at the
bone-prosthetic interface, promote hypertrophy of the
loaded bone, and avoid stress bypass of the host bone
around a stiff intramedullary stem [2]. The Compress1
Compliant Pre-Stress Implant (Biomet Inc, Warsaw, IN,
USA), a rotating-hinge knee prosthesis, was approved by
the FDA based on data from an unpublished short-term
feasibility study, conducted by the manufacturer, that
showed no difference in the acute complication rate and
equivalent functional outcome scores compared with a
cemented stem coupled to the same rotating-hinge articu-
lation (Orthopaedic Salvage System [OSSTM]; Biomet).
Published studies of this device include an investigation in
26 patients, among whom only 10 had followup longer than
24 months [4], a study of 26 patients followed for a period
of 0.3 to 9.2 years [23], and a study of 41 patients followed
for 3 to 97 months [9]. These studies suggest projected
10-year prosthetic survival is at least 80%, but the number
of cases is small and the number followed for this duration
is miniscule.
We therefore determined the survival of the Compress1
prosthesis at 5 and 10 actuarial years and identified the
failure modes for this form of prosthetic fixation. Finally,
the results were compared with those reported in a com-
prehensive review of the literature to establish the
superiority of this method of fixation compared to those
previously reported.
Patients and Methods
We retrospectively reviewed all 82 patients treated for
distal femoral reconstructions after major bone resection
from January 1998 to November 2008 at our institution.
This implant was used for all primary and secondary
(revision) femoral reconstructions, except for cases in
which the remaining bone was inadequate due to insuffi-
cient cortical thickness, patient age of more than 70 years,
metastatic disease, or prior irradiation of the femur
(Table 1). Surgery was performed for tumor reconstruction
in 80 patients and for noncancer revision TKA with mas-
sive bone loss in two patients. Followup was for a
minimum of 12 months or until implant removal (mean,
48.4 months; median, 43 months; range, 6–131 months).
Twenty-eight patients ([ 33%) were followed for longer
than 5 years. This study cohort includes the 41 patients in
our earlier study who were followed for a mean of
45 months (range, 3–97 months) [9]. One additional
patient underwent knee arthroplasty elsewhere and was
followed at our institution. This patient was included for
illustrative purposes because of an unusual complication
(Type IIB bone failure, see below) that helped to establish
our classification scheme of periprosthetic bone failure.
The patient was not included in our patient cohort total or
in the survivorship analysis. Patients were operated on for a
variety of cancer diagnoses (Table 2). Our institutional
review board approved this study.
All reconstructions at our institution were performed by
the authors (JHH, CDM, EAA, PJB). The procedure fol-
lowed the manufacturer’s recommended technique and has
been described elsewhere [21]. Briefly, it entailed a
sequence of steps after tumor or bone resection. The
medullary canal was reamed just enough to accept the
smallest anchor plug diameter of 12 mm or until there was
endosteal contact for wider medullary canals. The anchor
plug and traction bar were inserted into the canal. The
Table 1. Contraindications for use of the Compress1 device for
knee arthroplasty
Cortical thickness of less than 2.5 mm
Pre- or postoperative bone irradiation, precluding osteointegration
Extraarticular resection of knee (an articulated implant, such as the
Burstein-Lane1 implant, would be indicated)
Inadequate or unreconstructable soft tissue envelope (a very low-
profile implant, such as the GUEPAR1 implant, would be
indicated)
Metastatic disease that mandates immediate weightbearing (precludes
the requisite 3 months of protected weightbearing)
Inability to cooperate with the postoperative program of early,
protected weightbearing
Table 2. Patient demographic and clinical characteristics
Characteristic Value
Number of patients 82
Age (years)* 20.4 (14–63)
Sex (number of patients)
Male 40
Female 42
Reconstruction surgery (number of patients)
Primary 64
Revision 18
Tumor diagnosis (number of patients)
High-grade osteogenic sarcoma 64
Chondrosarcoma 5
Malignant fibrohistiocytoma 5
Giant cell tumor 3
Low-grade osteogenic sarcoma 2
Other tumor 1
No tumor (arthroplasty revision) 2
* The value is expressed as the median, with range in parentheses.
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muscle was bluntly split proximally to gain access to drill
the bone, rather than disrupting the periosteal blood supply
by stripping the bone. Using the outrigger for orientation
(Fig. 1), three holes were drilled sequentially through the
bone and anchor plug. After each hole was drilled, the drill
bit was left in place to transfix both cortices and the anchor
plug. After all three holes were drilled, the drill bits were
replaced with fixation pins, which were tapped into place.
We obtained a fluoroscopic image to confirm appropriate
pin placement and length. Next, we used the conical reamer
to prepare the surface of the host bone, constantly irrigating
to prevent burning the bone and maintaining the perios-
teum as much as possible. The appropriate spindle size
(small or large) and compressive force (400–800 pounds
[181–363 kg]) varied according to the bone size and cor-
tical thickness; compressive force levels recommended by
the manufacturer were used (400 pounds [181 kg] for
cortices 2.5–4.0 mm, 600 pounds [272 kg] for those
4.0–5.4 mm, 800 pounds [363 kg] for those C 5.5 mm).
The spindle and sleeve were placed over the intramedullary
traction bar. The compression nut was tightened, approxi-
mately one half-turn beyond the point that initial resistance
was felt, to compress the Belleville washers within the
implant’s compression chamber. Although the manufac-
turer does not precisely specify the amount of torque
required, the audible squeak of the washers signals that an
appropriate level of tightening has been achieved (Video 1;
supplemental materials are available with the online ver-
sion of CORR). The remainder of the segmental knee
arthroplasty was assembled as for the Orthopaedic Salvage
System (OSSTM) implant. In all patients, we used standard
components, including an overall 8-cm anchor plug-trac-
tion bar construct; we did not use recently available options
such as the 5-cm intramedullary implant. A typical case is
illustrated, in which the implant was indicated for a short
resection at the proximal femoral level (Fig. 2).
All patients underwent a similar rehabilitation regimen.
Continuous passive motion was initiated on Postoperative
Day 2 if there was no visible evidence of wound necrosis
and continued for approximately 2 weeks for approxi-
mately 18 hours/day. Patients started walking on the first
postoperative day using toe-touch weightbearing for
6 weeks, 50% weightbearing for an additional 6 weeks,
and then progressive weightbearing as tolerated. All were
fully weightbearing within a month. Patient adherence to
these guidelines was presumed. However, at least one
patient did not comply with recommended weightbearing
proscription and sustained a periprosthetic fracture and
implant failure after carrying a boat, necessitating revision.
Fig. 1A–B (A) A diagram illustrates the outrigger that aligns the
external drill guide with the intramedullary anchor plug. (B) A diagram
demonstrates how the drill bits (through the outer two holes) and ulti-
mately the fixation pins (through the central three holes) align.
Reprinted with permission of Biomet Inc from Compress1 Compliant
Pre-Stress Device Orthopaedic Salvage System: surgical technique.
Available at: http://www.biomet.com/orthopedics/getfile.cfm?id=1711&
rt=inline. 2012 Biomet Inc.
Fig. 2A–B The Compress1 is ideally suited for situations where
there is a short remaining intramedullary canal that can only
accommodate a short stem and fixation would be compromised.
(A) An image shows the femur of a 15-year-old patient who had
resection of a 25-cm osteogenic sarcoma of the distal femur that
extended into the proximal 1/3 of the diaphysis and required a 28-cm
resection. (B) A radiograph demonstrates how the surrounding bone
responds to the compliant force over time.
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Chemotherapy was resumed 2 to 3 weeks postoperatively
when appropriate for a patient’s diagnosis.
Patients were seen on a variable schedule based on the
patient’s diagnosis and disease activity. For high-grade
cancers, this was initially every 2 months and ultimately
once per year after a 4-year disease-free interval. Patients
with benign disease were seen every 3 to 6 months initially
and then annually after 4 years. Standard AP and lateral
radiographs were obtained at each visit. Radiographs were
examined for any deformation of the implant that sug-
gested bending or breaking of the device or fracture of the
bone. Any new or increased pain was noted. Radiographic
signs of loosening were not specifically quantified because,
to our knowledge, there is no suitable methodology for
evaluating loosening for this construct. Compress1 fixation
failure was defined as revision of the fixation mechanism
(anchor plug, traction bar, spindle, sleeve, or fixation pin)
for any reason. Revision of intraarticular components (eg,
polyethylene tibial bearing) that did not affect the bony
fixation was not counted as a fixation or implant failure.
Symptoms and signs of periprosthetic bone failure were
noted and typically manifested as patient complaints of
thigh pain and tenderness at the spindle-bone junction or
reports of thigh pain during examination when the hip was
rotated in the 90–90 position (supine, hip flexed 90, knee
flexed 90). In such instances, radiographs were examined
for evidence of a lack of osteointegration (ie, lack of
hypertrophy in the bony segment between the spindle and
the anchor plug and the presence of radiolucent lines at the
spindle-bone interface). The presence of implant, bone, or
symptomatic worsening prompted surgery.
In three patients who underwent revision surgery, we
analyzed the bone adjacent to the junction site, both by
visual inspection of the interface during surgery and by
microscopic analysis of standard hematoxylin and eosin
staining of decalcified samples.
Prosthesis-independent complications occurred but
seemingly at a rate similar to what we have observed for
other joint megaprostheses. There were three local recur-
rences; two were managed by local excision that did not
affect the prosthesis and one required an amputation that
removed the intact fixation. There were five prosthetic
infections, including four primary infections and one sec-
ondary infection. The primary infections were successfully
treated with washout, a change of intercalary segments, and
retention of the Compress1 fixation; there were no recur-
rences of infection. The secondary infection necessitated
amputation that included removal of the intact prosthesis.
The intact implants removed by the two amputations were
considered censored at the time of the removal.
We performed survival analysis of the device by the
Kaplan-Meier log-rank technique using SPSS1 Version
14.0 (SPSS Inc, Chicago, IL, USA). Survival was defined
as the time from the date of surgical implantation to the
date of prosthesis removal or latest followup.
A comprehensive review of the literature was performed
to place our results in context. A total of 718 articles were
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Fig. 3 The Kaplan-Meier survival analysis of the Compress1
prosthesis shows implant survivorship is 85% at 5 years (dashed
line) and 80% at 10 years (dotted line).
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13 patients experienced bone and/or device failure
Fig. 4 The flowchart shows the failure modes, treatment, and
outcomes of the 13 patients who experienced bone and/or device
failure after Compress1 implantation. ORIF = open reduction and
internal fixation.
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systematically read and reviewed. These were selected
by performing a PubMed search on July 14, 2012, using
the following key words: ‘‘megaprosthesis’’, ‘‘femoral
prosthesis’’, ‘‘knee replacement’’, and ‘‘tumor’’. Articles
that reported on the results of at least 20 patients for a mean
of 5 years’ followup were considered. The results were
Fig. 5A–C Type I failure is a
combination of interface and
bone failure. At (A) 3 and
(B) 6 months, the bone has not
integrated at the prosthetic inter-
face, and (C) at 10 months, it has
fractured between the spindle and
the anchor plug (arrow). Notably,
the sleeve and tension bar acted
like an inadequate stem and the
traction bar broke.
Fig. 6A–B Type IIA failures are fractures proximal to the anchor
plug fixation, perhaps at a stress transition point or, as in (A) this case
where the bone was thin due to endosteal erosion from a failed prior
stemmed implant (arrow). (B) The followup radiograph shows the
fracture healed with a dynamic hip screw fixation and onlay allograft
struts.
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further stratified based on studies that specified the number
of distal femoral resections/reconstruction, the diagnoses
for the surgical indications, and the prosthetic survivorship.
Results
Survivorship of the Compress1 fixation was 85% at
5 years and 80% at 10 years (Fig. 3). There were three
fixation failures in the first 2 years and five thereafter.
Failures occurred throughout the followup period. Never-
theless, only one failure occurred among the 28 patients
with more than 5 years of followup.
The modes of prosthetic failure that required revision
surgery varied (Fig. 4). There were eight failures of the
interface, due to aseptic loosening alone (three implants) or
aseptic loosening with periprosthetic fractures that affected
the interface (five implants).
Ten patients had periprosthetic bone failure. Five of the
eight patients with aseptic loosening had bone failure,
characterized by the absence of bone growth into the por-
ous spindle, collapse of the bone prosthesis interface, and
associated fracture between the anchor pins and the spin-
dle. As described above, revision was necessary. We
classified this mode of bone failure as Type I: affecting the
interface (Fig. 5). A second type of bone failure did not
require prosthetic revision and had two subtypes. The first,
Type IIA, included three fractures proximal to the implant
that did not disrupt the fixation (Fig. 6). These fractures
were treated and healed without any disruption of the
prosthetic-bone interface. Two patients had fractures that
healed uneventfully and retained their prosthesis with its
original Compress1 fixation after further followup of 5 and
9 years, respectively. One patient healed her fracture but
had an amputation for resultant osteomyelitis. Type IIB
bone failure, which did not disrupt the interface or extend
proximal to the anchor plug fixation pins, exhibited a
unique pattern (Fig. 7). The spindle showed ingrowth at the
posterior, but not anterior, aspect of the femur-spindle
interface. Fracture occurred in a coronal plane. The inte-
grated portion of the spindle remained attached to the
posterior bone that fractured off as a segmental piece
between the spindle and the anchor plug. There was some
anterior angulation of the fracture, associated with a bent or
broken traction bar. The anterior bone remained intact but
had not integrated into the device, and a small separation
was visible radiographically between anterior bone and the
spindle. The displacement was not enough to require
reduction. One patient from our cohort of 82 patients and
the additional patient who underwent distal femoral
reconstruction elsewhere had Type IIB failures. The first
patient underwent an open bone-grafting procedure, at
which time the fracture had already healed spontaneously.
Because the second patient exhibited the same pattern, the
fracture was allowed to heal without surgery, using only a
functional fracture cast brace.
We performed a retrieval analysis of tissue in three
patients from whom additional bone was removed, and
there was no infection or cancer recurrence. Clinically,
each patient had pain and radiographic failure. No well-
fixed implants were analyzed. The specimens showed
extensive osteonecrosis at the bone adjacent to the interface
in each of the three specimens studied to date (Fig. 8). No
other diagnostic histologic abnormalities were present.
Discussion
Compliant, self-adjusting compression technology is a
novel approach for durable prosthetic fixation of the knee.
Early results have been encouraging, but longer followup
Fig. 7A–B (A, B) Lateral radiographs taken 3 months apart show a
Type IIB failure. (A) The black arrow points to the fracture of the
posterior cortical segment that has moved with the spindle and the
megaprosthesis, and the white arrow points to the intact bone-spindle
interface where there has been some bone hypertrophy. Notably, the
anterior cortex has not integrated and there is no hypertrophy. (B) The
fracture healed spontaneously.
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reports are required from different centers. We therefore
determined the survival of the Compress1 prosthesis at 5
and 10 actuarial years and identified the fracture-associated
failure modes for this novel form of prosthetic fixation.
Several factors limit the interpretation of this study.
First, the absence of a control group makes it impossible to
compare results directly with fixation from conventional
cemented or uncemented intramedullary stems. This study
does not prove this fixation method is better than historic
options, even though the authors believe this is generally
true. Previously, we had hoped to address this question
through a prospective study protocol that would have
compared Compress1 fixation with press-fit and cemented
stems. The protocol was proposed to a musculoskeletal
oncology society, but the option of randomizing patients to
the Compress1 was rejected by the society’s surgeons;
hence, definitive comparative conclusions may never be
possible. However, in this study, we noted all 18 patients
who were revised to a Compress1 explicitly stated they
were more comfortable with this implant, suggesting it was
more stable and well fixed. Second, we only used the
compliant fixation with a single design of rotating-hinge
knee arthroplasty. Webber and Seidel [32] recently
reported combining compliant fixation with a different
body and articular design for pediatric limb salvage.
Although the results are unlikely to have been different if a
different knee design had been used, this question cannot
be answered by this study. Patients in our cohort were
treated over the course of a decade, and unrecognized
differences in the population or surgical technique could
have occurred. This problem plagues reviews of all low-
incidence conditions that require many years to accumulate
enough cases for analysis. Third, the minimum followup
was set at only 1 year to allow inclusion of the two Type
IIB cases of periprosthetic bone failure. The Kaplan-Meier
method and survival curves allow the reader to see the time
course of fixation failures and how the duration of followup
may affect the prosthetic survival.
We found the survivorship of Compress1 implants for
distal femoral reconstruction remained high, as confirmed
in nearly twice as many patients as we previously reported
and with followup extending to as long as 13 years. Eighty
percent of patients retained their prosthesis after an actu-
arial 10 years of followup. These results extend our earlier
report of 41 patients with a mean followup of 45 months
(range, 3–97 months) [9]. The durability exceeds the
Fig. 8A–C Type IIB failure shows (A) atrophy radiographically and (B, C) osteonecrosis histologically in two patient samples (Stain,
hematoxylin and eosin; original magnification, 940).
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survival of distal femoral/TKAs reported in most series, as
reviewed by Bhangu et al. [4] and summarized in our
systematic review (Table 3). Since 80% of patients with
osteogenic sarcoma are currently expected to survive
10 years, prosthetic survival has yet to exceed patient
survival. While the Compress1 implant performs at least
as well over time as prostheses with other forms of bone
fixation, further improvement of prosthetic durability is
needed, especially for young patients with good long-term
prognosis from their cancer. This high rate of prosthetic
survival is encouraging but also suggests there may be
factors regarding the patients, the surgery, or the sub-
sequent management that influence the durability of the
prosthesis. Notably, this analysis may be site specific and
may not apply to compliant compression fixation in other
sites [22] or under different clinical circumstances [2]. The
time course of failure sheds some light on the nature of the
fixation and its durability. Contrary to our previous report,
on more than one occasion, the implant failed after the first
year. Failures continued throughout the followup period.
Indeed, five needed revision more than 2 years after
implantation. However, only one of 28 implanted for more
than 5 years subsequently failed. Thus, the concept that
this form of biologic fixation would be long-lasting if it had
a chance to become established was neither proven nor
disproven in this cohort. It highlights how the durability is
time dependent and the results can apparently be different
depending on the time frame of the analysis.
The unique fixation method of this prosthesis showed a
unique spectrum of failure mechanisms. Aseptic loosening,







Unwin et al. [31] 1993 218 Distal femur Stanmore 65 10
Langlais et al. [15] 2006 26 Distal femur GUEPAR1 II or custom
press-fit cemented
92 12.5
Myers et al. [20] 2007 332 Distal femur Stanmore 67 10
Zimel et al. [33] 2009 47 Distal femur Howmedica 39 OSSTM 8 36 10
Farfalli et al. [9] 2009 50 Distal femur OSSTM uncemented 71 10
Shehadeh et al. [27] 2010 101 Distal femur MSRSTM 70 10
Bergin et al. [3] 2012 93 Distal femur MRSTM/GMRSTM 73 10
Tan et al. [28] 2012 78 Distal femur Custom 71 10
Roberts et al. [26] 1991 135 Distal femur Stanmore 72 5
Horowitz et al. [11] 1993 61 Distal femur Burstein-Lane1 78 5
Kawai et al. [12] 1999 25 Distal femur Finn1 88 5
Griffin et al. [10] 2005 74 Distal femur KMFTR
TM
uncemented 70 14
Bruns et al. [8] 2007 13 Distal femur MUTARS1 87 7
Kinkel et al. [13] 2010 49 Distal femur MUTARS1 57 5
Matsumine et al. [17] 2011 69 Distal femur Kyocera 85 5
Ritschl et al. [25] 1992 206 Mixed KMFTRTM 73 10
Unwin et al. [31] 1993 218 Mixed Stanmore 65 10
Unwin et al. [30] 1996 1001 Mixed Stanmore 67.4 10
Mascard et al. [16] 1998 90 Mixed GUEPAR1 60 10
Mittermayer et al. [18] 2001 41 Mixed KMFTRTM 53 11
Plo¨tz et al. [24] 2002 64 Mixed Custom 25 10
Bickels et al. [6] 2002 110 Mixed MSRSTM 88 10
Biau et al. [5] 2006 56 Mixed Custom 50 11
Morgan et al. [19] 2006 105 Mixed HMRSTM 59 10
Current study 2012 82 Distal femur Compress1 80 10
* Prostheses include Stanmore (Stanmore Implants Worldwide Ltd, Elstree, UK); GUEPAR1 II (Stryker France, Lyon, France);
OSSTM = Orthopaedic Salvage System (Biomet Inc, Warsaw, IN, USA); MSRSTM = Modular Segmental Reconstruction System (Stryker
Howmedica, Mahwah, NJ, USA); MRSTM/GMRSTM = Modular Replacement System/Global Modular Replacement System stems (Stryker
Howmedica); Burstein-Lane1 implant (Biomet Inc, Warsaw, IN, USA); Finn1 (Biomet Inc); KMFTRTM = Kotz Modular Femur Tibia
Reconstruction System (Howmedica, Rutherford, NJ, USA); MUTARS1 = Modular Universal Tumour And Revision System (Implantcast
GmbH, Buxtehude, Germany); Kyocera (Kyocera Medical Corp, Osaka, Japan); HMRSTM = Howmedica Modular Replacement System
(Howmedica); patients in this study were also included in the analysis by Shehadeh et al. [27].
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commonly reported with other cemented and uncemented
prostheses, also occurred with this implant. However, the
aseptic loosening differed from that seen with other
implants since bone ingrowth failed despite the continu-
ously adjusting compression generated by the Belleville
washers in the compression chamber. Retrieval specimens
of these failures showed avascular necrosis of the under-
lying bone, in distinction to the viable bone found in well-
fixed implants that were explanted for other reasons such as
infection or tumor recurrence [7, 14]. A second, perhaps
related unique finding was fracture or crumbling of the
underlying bone between the anchor plug and the spindle.
This was present in one patient who was included as part of
a multicenter report on periprosthetic fractures around
Compress1 devices [29]. The phenomenon has not been
singled out for analysis. It could not be determined whether
the osteonecrosis led to fatigue failure of the bone or the
fracture caused osteonecrosis near the interface. The
pathophysiology of these failures is unproven. Treatment
of fractures related to prosthetic failure was not the focus of
this study but is reportedly relatively easy and yields pain-
free, functional reconstructions with few complications
[1, 29].
Our analysis demonstrates a survivorship of 80% for
Compress1 knee arthroplasty; the only published report
demonstrating better survivorship after 10 years is that of
Langlais et al. [15], who utilized custom-made press-fit
femoral revision stems in 20 of the 26 joint arthroplasties.
Thus, this report is the most comprehensive to date on an
FDA-approved device for this unique form of prosthetic
fixation.
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